BR112018016725A2 - pharmaceutical composition to prevent and treat sleep disorders - Google Patents

pharmaceutical composition to prevent and treat sleep disorders

Info

Publication number
BR112018016725A2
BR112018016725A2 BR112018016725A BR112018016725A BR112018016725A2 BR 112018016725 A2 BR112018016725 A2 BR 112018016725A2 BR 112018016725 A BR112018016725 A BR 112018016725A BR 112018016725 A BR112018016725 A BR 112018016725A BR 112018016725 A2 BR112018016725 A2 BR 112018016725A2
Authority
BR
Brazil
Prior art keywords
sleep disorders
pharmaceutical composition
prevent
treat sleep
relates
Prior art date
Application number
BR112018016725A
Other languages
Portuguese (pt)
Inventor
Konstantinovich Syrov Kirill
Viktorovich Nesteruk Vladimir
Original Assignee
Valenta Intellekt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valenta Intellekt Ltd filed Critical Valenta Intellekt Ltd
Publication of BR112018016725A2 publication Critical patent/BR112018016725A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

a invenção se refere ao campo da medicina e à indústria químico-farmacêutica e refere-se aos agentes para uso no caso de transtornos do sono. uma composição farmacêutica para iniciar e manter o processo do sono e para prevenir, em animais e seres humanos, condições associadas a vários tipos de transtornos do sono, em que a dita composição é caracterizada por incluir quantidades eficazes de succinato de doxilamina e melatonina de liberação lenta. o resultado técnico consiste em efeitos terapêuticos sinérgicos, sucessão biológica e efeitos colaterais reduzidos.The invention relates to the field of medicine and the chemical-pharmaceutical industry and relates to agents for use in the case of sleep disorders. A pharmaceutical composition for initiating and maintaining the sleep process and for preventing, in animals and humans, conditions associated with various types of sleep disorders, wherein said composition is characterized by including effective amounts of doxylamine succinate and melatonin release. slow. The technical result consists of synergistic therapeutic effects, biological succession and reduced side effects.

BR112018016725A 2016-02-18 2017-02-16 pharmaceutical composition to prevent and treat sleep disorders BR112018016725A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2016105535A RU2620855C1 (en) 2016-02-18 2016-02-18 Pharmaceutical composition for sleep disorders prevention and treatment
PCT/RU2017/000077 WO2017142442A1 (en) 2016-02-18 2017-02-16 Pharmaceutical composition for preventing and treating sleep disorders

Publications (1)

Publication Number Publication Date
BR112018016725A2 true BR112018016725A2 (en) 2019-04-30

Family

ID=59032329

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018016725A BR112018016725A2 (en) 2016-02-18 2017-02-16 pharmaceutical composition to prevent and treat sleep disorders

Country Status (9)

Country Link
KR (1) KR20180101539A (en)
CN (1) CN108697645A (en)
BR (1) BR112018016725A2 (en)
CL (1) CL2018002337A1 (en)
EA (1) EA201891647A1 (en)
HK (1) HK1255631A1 (en)
MX (1) MX2018009921A (en)
RU (1) RU2620855C1 (en)
WO (1) WO2017142442A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517040A (en) * 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド Melatonin combination therapy to improve sleep quality
US9700548B2 (en) * 2011-06-09 2017-07-11 Requis Pharmaceuticals Inc. Antihistamines combined with dietary supplements for improved health
FR3000896B1 (en) * 2013-01-14 2016-08-26 Philippe Perovitch GALENIC FORM FOR ADMINISTRATION OF ACTIVE INGREDIENT (S) FOR ACCELERATED INDUCTION OF SLEEP AND / OR TREATMENT OF SLEEP DISORDERS
DK2964185T3 (en) * 2013-03-05 2022-02-14 Requis Pharmaceuticals Inc PREPARATIONS FOR THE TREATMENT OF SLEEP-RELATED RESPIRATORY DISORDERS

Also Published As

Publication number Publication date
CL2018002337A1 (en) 2018-11-30
MX2018009921A (en) 2018-11-09
KR20180101539A (en) 2018-09-12
HK1255631A1 (en) 2019-08-23
RU2620855C1 (en) 2017-05-30
EA201891647A1 (en) 2018-12-28
WO2017142442A1 (en) 2017-08-24
CN108697645A (en) 2018-10-23

Similar Documents

Publication Publication Date Title
CL2016002517A1 (en) Use of r-2-4-2-ethoxy-3-4-trifluoromethylphenoxypropyl-thio-2-methylphenoxy acetic acid or a salt thereof in the manufacture of a medicament to treat a condition that is a non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
BR112017003546A2 (en) heterocyclic amides as rip1 kinase inhibitors as drugs
NI201600071A (en) AUTOTAXIN INHIBITOR COMPOUNDS
BR112017014067A2 (en) composition to treat diseases related to il-6
CR20170129A (en) USE OF A DUAL GLP-1 / GLUCAGON RECEPTOR AGONIST OF LONG-TERM ACTION FOR THE TREATMENT OF NON-ALCOHOLIC FAT LIVER DISEASE
BR112017007072A2 (en) triazolopyridine compounds and methods for treating cystic fibrosis
BR112017005693A2 (en) method for treating and / or preventing liver disease, and, pharmaceutical composition.
CO2018013077A2 (en) Arginase inhibitors and their therapeutic applications
BR112018010671A8 (en) shape-changing drug delivery devices and methods
CL2019001214A1 (en) Pharmaceutical composition, methods for treatment and their uses.
NI201600070A (en) AUTOTAXIN TETRAYCLIC INHIBITORS
CL2019000625A1 (en) Fxr agonist combination.
AR094707A1 (en) COMPOUND OF QUINAZOLIN-4-AMINA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE TREATMENT OF A DISEASE MEDIATED BY THE RIP2 KINASE
ECSP16086247A (en) (S) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
UY37729A (en) NEW COMPOUNDS THAT INHIBIT THE ACTIVITY OF Nav1.7
CL2013001910A1 (en) Compounds derived from phenyl isoxazole; method to prepare them; pharmaceutical composition that includes them; combination that includes them together with another therapeutic or preventive agent of viral infections; method to prevent or treat viral infections; and its use for the treatment of viral infections.
BR112016026470A8 (en) hsp70 modulating compound, pharmaceutical composition comprising it and use of said compound
CO2017001899A2 (en) Cancer treatment with alpha-amylase inhibitor in companion animals
ECSP16086232A (en) (R) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
CL2016001843A1 (en) Use of a composition comprising a) a compound of defined formula (ia) or a salt thereof and b) a pharmaceutically acceptable carrier or excipient to prepare a medicament useful for treating an allergic condition in a mammal.
PH12020550532A1 (en) Agent for preventing or treating small intestinal injury induced by non-steroidal anti-inflammatory drug and proton pump inhibitor
BR112018016725A2 (en) pharmaceutical composition to prevent and treat sleep disorders
BR112017028025A2 (en) iron-carbohydrate complex for the treatment of iron deficiency in a fetus or baby
BR112019008516A2 (en) 3,4-bipyridyl pyrazole derivative, and method of preparation for it and medical application thereof
BR112018015483A2 (en) stable solid pharmaceutical formulations containing 2- (2-nitro-4-trifluoromethyl-benzoyl) -1,3-cyclohexanedione

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) [chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements